WMS Partners LLC maintained its position in MiMedx Group, Inc (NASDAQ:MDXG) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,259 shares of the medical equipment provider’s stock at the end of the first quarter. WMS Partners LLC’s holdings in MiMedx Group were worth $250,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of MDXG. State of Alaska Department of Revenue boosted its position in shares of MiMedx Group by 1.3% in the first quarter. State of Alaska Department of Revenue now owns 11,100 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 140 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of MiMedx Group by 15.4% in the first quarter. Victory Capital Management Inc. now owns 14,616 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 1,952 shares during the period. Tudor Investment Corp Et Al acquired a new stake in shares of MiMedx Group during the fourth quarter worth $159,000. Cutter & CO Brokerage Inc. purchased a new stake in shares of MiMedx Group during the fourth quarter worth approximately $170,000. Finally, LS Investment Advisors LLC raised its stake in shares of MiMedx Group by 343.5% in the first quarter. LS Investment Advisors LLC now owns 18,611 shares of the medical equipment provider’s stock worth $177,000 after buying an additional 14,415 shares during the last quarter. 55.77% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

MiMedx Group, Inc (NASDAQ:MDXG) opened at 15.02 on Wednesday. The stock has a 50 day moving average price of $14.38 and a 200 day moving average price of $10.39. The stock has a market capitalization of $1.59 billion, a PE ratio of 107.29 and a beta of 1.35. MiMedx Group, Inc has a 12 month low of $6.94 and a 12 month high of $15.75.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Friday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.07. MiMedx Group had a return on equity of 12.25% and a net margin of 5.72%. The firm had revenue of $72.60 million during the quarter, compared to analyst estimates of $72.60 million. During the same quarter last year, the business posted $0.04 earnings per share. The business’s quarterly revenue was up 36.1% compared to the same quarter last year. On average, equities research analysts forecast that MiMedx Group, Inc will post $0.30 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “WMS Partners LLC Has $250,000 Stake in MiMedx Group, Inc (MDXG)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/06/21/mimedx-group-inc-mdxg-position-maintained-by-wms-partners-llc-updated-updated-updated.html.

Several equities analysts have recently issued reports on the company. First Analysis lowered MiMedx Group from an “equal weight” rating to an “underweight” rating and set a $11.00 target price for the company. in a research report on Tuesday, May 23rd. Piper Jaffray Companies started coverage on MiMedx Group in a research note on Friday, March 3rd. They issued an “overweight” rating and a $10.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of MiMedx Group in a research report on Wednesday, April 26th. TheStreet raised MiMedx Group from a “c+” rating to a “b” rating in a report on Thursday, March 16th. Finally, Zacks Investment Research raised MiMedx Group from a “sell” rating to a “hold” rating in a report on Tuesday, February 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $12.00.

In other MiMedx Group news, insider William Charles Taylor sold 26,000 shares of the firm’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $11.40, for a total value of $296,400.00. Following the completion of the sale, the insider now owns 540,460 shares of the company’s stock, valued at $6,161,244. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 132,571 shares of company stock valued at $1,823,086. 12.40% of the stock is owned by insiders.

MiMedx Group Company Profile

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Receive News & Stock Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related stocks with our FREE daily email newsletter.